89Zr-rituximab PET/CT for detection of central nervous system lymphoma

Completed

• Conditions: brain tumour; lymphoma; 10025323; 10029211

• Registration Number: NL-OMON42205
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

- Patients who have signed informed consent
- Age >= 18 years
- MR suspicion of a primary CNS lymphoma (homogeneous contrast enhancement, low MRI ADC values).

Exclusion Criteria

- Pregnancy

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main outcome of the study is the performance of 89Zr- rituximab PET/CT in<br /><br>diagnosing CSN lymphoma. The diagnostic gold standard will be histological<br /><br>biopsy and pathology diagnosis of PCNSL. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>